A preclinical evaluation program is currently in place with LabTAU, unit U1032 of INSERM in Lyon, France.
The first prototypes of MRI compatible probes were constructed and tested in animal models. They have demonstrated the effectiveness of a device capable of generating rapid tissue necrosis in brain tissue under MR guidance.
With these results, more sophisticated prototypes are currently being built and tested. The encouraging results of these tests have enabled CarThera® to launch the development of probes that meet the standards required for the launch of clinical trials in humans.